Podcasts about Phase

Your daily news in under three minutes. At Al Jazeera Podcasts, we want to hear from you, our listeners. So, please head to https://www.aljazeera.com/survey and tell us your thoughts about this show and other Al Jazeera podcasts. It only takes a few minutes! Connect with us: @AJEPodcasts on X, Instagram, Facebook, and YouTube

In this podcast episode, Dr. Jonathan H. Westover talks with Lamell J. McMorris about his book, THE POWER TO PERSIST: 8 Simple Habits To Build Lifelong Resilience. Lamell J. McMorris is a nationally recognized entrepreneur, activist, and changemaker dedicated to advancing equity and revitalizing underserved communities. Growing up on the South Side of Chicago, he went on to find phenomenal success as a D.C. policymaker, a consultant in the financial and professional sports arenas, and a civil and human rights advocate. McMorris is the founder and CEO of the Washington, D.C.-based company Phase 2 Consulting, which offers strategic insight and external affairs services to some of the nation's leading decision-makers in the private, public, and nonprofit sectors, including Fortune 100 companies. He is also founder and managing principal of Greenlining Realty USA, a comprehensive urban redevelopment firm dedicated to neighborhood investment, redevelopment, housing rehabilitation, and home improvement in low-income communities. He holds a BA in Religion and Society from Morehouse College, a MDiv in Social Ethics and Public Policy from Princeton Theological Seminary, and a DLP in Law and Policy from Northeastern University. Check out all of the podcasts in the HCI Podcast Network!

Send us a textWelcome back Rounds Table Listeners! In our year-end episode, Drs. Mike and John Fralick discuss five important research studies published in 2025:Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO) (0:00 – 4:20)Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) (4:21 – 9:30)Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC) (9:31 – 15:03)Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial (FRESH-UP) (15:04 – 18:09)Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) (18:10 – 23:49)The Good Stuff (23:50 – 25:27):Toronto Star Santa Claus Fund, Calgary Food Bank, The War Amps Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Send us a textIn this episode of WTR Small-Cap Spotlight, host Tim Gerdeman and analyst Robert Sassoon speak with Shaun Bagai, CEO of RenovoRx (NASDAQ: RNXT). The company is pioneering targeted oncology therapies and commercializing RenovoCath™, an FDA-cleared multi-specialty local drug delivery device for high unmet needs. We discuss the innovation and advantages of its TAMP™ (Trans-Arterial Micro-Perfusion) platform—powered by the proprietary dual-balloon catheter—and how it sets RenovoRx apart in treating hard-to-reach hypovascular tumors like pancreatic cancer. The conversation also covers RenovoCath's commercialization strategy and key milestones in its Phase 3 clinical trial aimed at proving the platform's delivery superiority over the current standard of care.

SpaceX IPO coming – huge increase in valuation over past 3 months Happy Hanukah – Eight Crazy Nights Now Kevin AND Kevin PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Last Chance for CTP Cup 2025 participants - Happy Hanukah - Eight Crazy Nights - Sad News - Rob Reiner - Fed decision is out.... - Overdue eco reports coming this week Markets - Oracle still problematic - SpaceX IPO coming - huge increase in valuation over past 3 months - Another Bankruptcy - cleaning up is not good business - Oh my - Now Kevin AND Kevin - Weight loss game continues - One thing saved for last - a doozie... Tesla -  - All time High - Prospect of Robotaxi - Even though sales hitting multi-year lows Wall Street Never Sleeps? - Nasdaq files to extend trading to 23 hours on weekdays - Banks concerned about investor protections, costs, liquidity, volatility risks of nonstop trading - Proponents argue round-the-clock trading benefits global investors - That may create some additional volatility potential SpaceX - SpaceX aims for a potential $1.5 trillion market cap with an Initial Public Offering in 2026, which could become the largest IPO in history - July 2025 tender valuation was $400B - Dec 14th (4 months later) $800B - Starlink is the primary money winner of this deal - Tesla shares climbing even with nothing behind it - seemingly in sympathy for this IPO ---- TESLA does not have ownership of SpaceX - OH - this could be the reason....U.S. deliveries dropped significantly in November—the lowest since early 2022—but this weakness has been overshadowed by the enthusiasm for autonomy. Rob Reiner - A son of legendary Hollywood director Rob Reiner and his wife, producer Michele Singer Reiner, Nick Reiner, is being held on suspicion of murder following their deaths, according to Los Angeles Police Department Chief Jim McDonnell. He's being held on $4 million bail. - Citing law enforcement sources and family friends, ABC News reported on Monday that Nick Reiner had recently returned to live at his parents' South Chadbourne Avenue home. The move was described as a temporary arrangement intended to help him stabilize. - Not going to discuss the Truth Social post about this tragedy HEADLINE ALERT - "Copper could hit ‘stratospheric new highs' as hoarding of the metal in U.S. continues" - Copper has gone from 5.77 to 5.30 (July to today) - 6 Tops at this price since 2011 - Not seeing this as per the headline - seems like a Hunt Brothers special from the 1980s - CORNERING THE MARKET ---1980 - Silver went from $11 to $50 then crashed, bankrupting the Hunt Bros - after COMEX changed rules forcing them to cover positions Bankruptcy - After 35 years, the maker of the Roomba robot vacuum filed for bankruptcy protection late Sunday night. Following warnings issued earlier this year that it was fast running out of options, iRobot says it is entering Chapter 11 protection and will be acquired by its contract manufacturer, China-based Picea Robotics. - The company says it will continue to operate “with no anticipated disruption to its app functionality, customer programs, global partners, supply chain relationships, or ongoing product support.” - Remember that Amazon  - The Amazon buyout of iRobot, maker of Roomba, was announced in 2022 for $1.7 billion but ultimately failed in January 2024 due to significant regulatory pushback, primarily from the EU, over anti-competitive concerns. -- Amazon walked away with a $94 million termination fee Fed Pick - President Donald Trump said Friday that Kevin Warsh has moved to the top of his list as the next Federal Reserve chair, though Kevin Hassett also remains in contention, according to the Wall Street Journal. - Interesting that this comes days after Hassett said that we would not let outside suggestions influence his voting - ---In addition to putting heavier weight on Warsh getting the job, Trump repeated an assertion he has made in the past that the Fed chair ought to consult the president about interest rate decisions. - Also of interest, prediction markets had Hassett at 95% probability - now it moved to 50% - big payday for people in the know. Housing Prices - Average home price is DOWN on  year-over-year basis - First time on national level since 2024 - Active listings in November were nearly 13% higher than November 2024, but new listings were just 1.7% higher --- Houses are on market longer - - Prices in Austin, Texas, are down 10% from last year; in Denver, they're down 5%, according to Parcl Labs. Tampa, Florida, and Houston both saw prices fall 4%, and Atlanta and Phoenix saw price decreases of 3%. More Hosing Related -  Zillow shares plunged more than 9% on Monday on worries that the online real estate platform could have a big new competitor: Google Search. - Google appears to be running tests on putting real estate sale listings into its search results. Overdue Eco  - Black Hole - The U.S. Bureau of Labor Statistics on Tuesday releases its long-awaited combined employment reports for October and November, but a number of key details will be missing after the government shutdown prevented data collection, including October's unemployment rate, resulting in the first-ever gap in that critical data series since inception in 1948. - NICE JOB GANG! - Some of the data will be estimated. - It said it would not publish the headline CPI number or the so-called core CPI, which strips out the volatile food and energy components, for October. "BLS cannot provide specific guidance to data users for navigating the missing October observations," the agency said. Some Updates - Some info coming in are estimates - some delayed - Unemployment at 4.6% - Latest report shows +64,000 added - ISM Manufacturing and Non-manufacturing - both slowed over the last month The Fed - Meanwhile the Fed cuts rates.... - A Federal Reserve split over where its priorities should lie cut its key interest rate Wednesday in a 9-3 vote, but signaled a tougher road ahead for further reductions. - The FOMC's “dot plot” indicated just one more reduction in 2026 and another in 2027, amid considerable disagreement from members about where rates should head. - In addition to the rate decision, the Fed also announced it will resume buying Treasury securities. The central bank will start by buying $40 billion in Treasury bills, beginning Friday. - Markets were all over the place on this as it was a little confusing at first - then it seemed that everyone loved (for one day) - Why is the Fed moving up Treasury purchases to "immediately" from a few months from now? - AND - dissension ! A larger group  that usual of regional Fed bank presidents signaled they opposed the cut, and six policymakers said the benchmark federal funds rate should end 2025 in a range of 3.75% to 4%, suggesting they opposed the move. - Long bonds have not moved at all on this news. Costco Earnings - Costco beat Wall Street's fiscal first-quarter sales and revenue expectations. - Sales rose 8.2% and digital sales jumped 20.5% compared with the year-ago quarter. - Costco surpassed Wall Street's quarterly expectations and posted year-over-year sales growth of 8.2% as the retailer attracted more digital sales and opened new locations. - Earnings per share: $4.50 vs. $4.27 expected - Revenue: $67.31 billion vs. $67.14 billion expected - Costco does not provide year ahead guidance - Shares down from a recent high of $855 Costco Fun Facts - About 4.5 million pies were sold in the three days before Thanksgiving, which is equivalent to roughly 7,000 pies per warehouse. -  These were bakery pies (e.g., pumpkin, apple), - Costco had more than $250 million in non-food online orders on Black Friday, a record for Costco's U.S. e-commerce business. - Approximately 358,000 whole pizzas were served at Costco's U.S. food courts, a 31% jump from last year. (500 pizza's per store) Fat No More - Retatrutide - Eli Lilly said its next-generation obesity drug delivered what appears to be the highest weight loss seen so far in a late-stage trial and reduced knee arthritis pain, clearing the first of several upcoming studies on the weekly injection. - In a 48-week Phase 2 study, participants on the highest dose lost an average of 24% of their body weight. - Recent Phase 3 results showed patients on the highest dose lost an average of 28.7% of their body weight after 68 weeks. - The trials also showed improvements in related health conditions, including knee osteoarthritis pain, blood pressure, and liver fat - This triple action is what makes retatrutide potentially more effective for weight loss than existing medications like Zepbound (tirzepatide), which targets two receptors, or Wegovy (semaglutide), which targets only one. Paypal - PayPal Holdings Inc. applied to become a bank in the US, looking to take advantage of the Trump administration's openness to financial-technology companies entering the banking system. - The payments-focused firm submitted applications to the Federal Deposit Insurance Corp. and the Utah Department of Financial Institutions to form a Utah-chartered industrial loan company, PayPal said in a statement Monday. - If approved, PayPal Bank would help the firm bolster its small-business lending capabilities, according to the statement, which said the company has provided access to more than $30 billion in loans and capital since 2013. Ford - Management Confused - Instead of planning to make enough electric vehicles to account for 40 percent of global sales by 2030—as it pledged just four years ago—Ford says it will focus on a broader range of hybrids, extended-range electrics, and battery-electric models, which executives now say will account for 50 percent of sales by the end of the decade. - The automaker will make hybrid versions of almost every vehicle in its lineup, the company says. - All in on EVS cost them -  Ford expects to record about $19.5 billion in special items, mostly during the fourth quarter. ---- The charges are related to a restructuring of its business priorities and a pullback in its all-electric vehicle investments. Australia - Australia has implemented a groundbreaking ban preventing children under 16 from accessing major social media platforms like TikTok, Instagram, and Facebook, effective December 2025, to protect them from harm, with significant fines for companies failing to enforce it, though messaging apps and gaming platforms are currently exempt. - Reddit is suing - Facebook, Instagram, Snapchat, Threads, TikTok, X (Twitter), YouTube, Reddit, Kick, and Twitch are all banned for kids under 16. - Thoughts on this? Saved For Last - Of all the eye-popping numbers that Oracle Corp. published last week on the costs of its artificial-intelligence data center buildout, the most striking didn't appear until the day after its earnings press release and analyst call. - The more comprehensive 10-Q earnings report that appeared on Thursday detailed $248 billion of lease-payment commitments, “substantially all” related to data centers and cloud capacity arrangements, the business-software firm said. These are due to commence between now and its 2028 financial year but they're not yet included on its balance sheet. - That's almost $150 billion more than was disclosed in the footnotes of September's earnings update. Love the Show? Then how about a Donation? The Winner for iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Participants: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Collective Mining has expanded the Ramp Zone. We are seeing new drill results from NGEx and the Phase 4 program at Lunahuasi. New Break Resources have new drill results to report. Drilling at 1911 Gold's Ogama-Rockland deposit has commenced. District Metals applied for more mineral licenses in Sweden. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

​Attorney General Pam Bondi's recent announcement of releasing additional files related to Jeffrey Epstein has been met with skepticism, particularly following the underwhelming "Phase 1" release. The initial batch, which Bondi had hyped as containing "sick" revelations, primarily consisted of previously available flight logs and heavily redacted documents, offering little new information. This anticlimactic disclosure led to disappointment among the public and conservative influencers, who had anticipated more substantial revelations. Critics argue that the fanfare surrounding the release was disproportionate to its actual content, raising questions about the transparency and intentions behind these actions.In response to the backlash, Bondi has assured the public that more comprehensive documents will be forthcoming, blaming the initial shortcomings on the FBI's alleged withholding of thousands of pages. She has demanded that these documents be delivered to her office promptly, emphasizing a commitment to full transparency. However, given the previous overpromising and underdelivering, many remain skeptical about the authenticity and potential impact of the upcoming releases.to contact me:bobbycapucci@protonmail.comsoruce:Attorney General Pam Bondi insists more Jeffrey Epstein files are being released – despite disastrous ‘phase 1' | The IndependentBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Join me for an empowering conversation with Dr. Amy Killen, a board-certified emergency physician turned longevity expert, as we explore how women can thrive in their "Queen Phase"—the years following the loss of the protective "estrogen shield" . We dive deep into the nuances of Hormone Replacement Therapy, celebrating the recent FDA updates on estrogen and dispelling myths about testosterone for women . Dr. Killen breaks down the science of stem cells, explaining the difference between autologous (bone marrow/fat) and allogeneic sources, and shares vital red flags to watch for in regenerative clinics . We also discuss the critical link between mitochondrial health and sexual longevity, the potential of peptides like PT-141 and GHK-Cu, and why heavy lifting and sleep are non-negotiable for aging well . Guest Information: Dr. Amy Killen is the Co-Founder of Humanaut Health and the founder of the Human Optimization Project. You can find her at https://biorestoration.com/dt_team/person-01/ and on Instagram @DrAmyBKillen .

In this episode of the IoT For All Podcast, Barry Libert, Chairman and CEO of HiveMQ, joins Ryan Chacon to discuss moving past the pilot phase in industrial IoT and AI. The conversation covers viewing businesses as data streaming entities, the importance of understanding one's data collection processes, aligning different tiers of employees to achieve success, the shift from connectivity to AI data platforms, the role of agentic workflows, and the type of leadership required to navigate the evolving landscape of data and AI.Barry Libert is the Chairman and CEO of HiveMQ. He has spent 40+ years as a board member, CEO, and serial entrepreneur. He founded and exited several businesses, advised more than 350 CEOs, and served on more than 35 boards in his career. Most recently, Barry transformed Anaconda into a unicorn, adding $100M in new ARR in 18 months based on a proprietary open- source/open-core commercialization GTM playbook he co-designed and implemented.Barry is focused on AI platforms with network effects and data moats. He has co-authored 6 books, 20+ ebooks, and 500+ articles in the WSJ, NYT, HBR, MIT, and Forbes. He has appeared on CNN, CNBC, Fox, NPR, and delivered 500+ speeches to 250,000+ people globally. Barry began his career with McKinsey & Company, was a managing director of John Hancock's $2B Real Estate Equity arm, and was a partner at Arthur Andersen. Barry is a graduate of Tufts University (BA) and Columbia University (MBA).HiveMQ is the Industrial AI Platform helping enterprises move from connected devices to intelligent operations. Built on the MQTT standard and a distributed edge-to-cloud architecture, HiveMQ connects and governs industrial data in real time, enabling organizations to act with intelligence. With proven reliability, scalability, and interoperability, HiveMQ provides the foundation industrial companies need to operationalize AI, powering the next generation of intelligent industry. Global leaders including Audi, BMW, Eli Lilly, Liberty Global, Mercedes-Benz, and Siemens trust HiveMQ to run their most mission-critical operations.Discover more about IoT and AI at https://www.iotforall.comFind IoT solutions: https://marketplace.iotforall.comMore about HiveMQ: https://www.hivemq.comConnect with Barry: https://www.linkedin.com/in/barrylibert/Subscribe on YouTube: https://bit.ly/2NlcEwmJoin Our Newsletter: https://newsletter.iotforall.comFollow Us on Social: https://linktr.ee/iot4all

This week's episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).

PLD & PJ go over The Incredible Hulk which was the forgotten stepchild until Brave New World came out! Recorded 7-8 months ago and made public now as we unveil Phase 1 during my hiatus!

In this episode, Paula Swope shares her unfiltered, real-life experience with peptides—what actually happened when she started them, what helped, and what went sideways. This is not a “Peptides 101” episode. It's a candid walkthrough of her personal journey with Retatrutide, Sermorelin, and a Tesamorelin/Ipamorelin/BPC-157 blend, including the unexpected side effects, sleep disruptions, appetite changes, and the adjustments that ultimately made the protocol work for her. Paula breaks down how growth-hormone–stimulating peptides affected her body, why one blend left her feeling awful, how Sermorelin became a sleep game-changer, and what it's actually like to use Retatrutide—the experimental triple-agonist weight-loss drug from Eli Lilly that's making headlines after completing Phase 3 trials. She also discusses appetite suppression, slow and sustainable weight loss at midlife, muscle preservation, protein intake, constipation, and why sleep quality may be the most underrated factor in fat loss and emotional regulation. This episode is not medical advice. Paula is not a doctor and does not tell anyone what to take or how to dose. She shares her experience, emphasizes the importance of working with a licensed medical professional, and warns about the growing gray and black markets for unregulated peptides. If you're curious about peptides but want an honest, grounded perspective—without hype, fear-mongering, or social media nonsense—this episode offers clarity, nuance, and lived truth.

If YOU'RE ready to make real, sustainable change in your life, jump on a free call with us - https://physiquedevelopment.typeform.com/to/ToP9TYLEOver the past few episodes, Sue and Alex have unpacked the truth about bulking—why a massive surplus isn't necessary and what actually drives muscle growth. In today's episode, they dive into how long your muscle-building phase should be. So if you want efficient results and want to feel good while getting there, this episode is for you.They break down what a real, effective, feel-good build phase looks like, and what needs to be addressed before the build even begins. They also explain the optimal length for a muscle-building phase and why staying in hypertrophy for months on end often leads to stalled progress, not better results. Muscle growth requires complementary phases and intentional planning, not just grinding harder in the gym.Because you don't need more effort, you need a better system—one that supports your body, respects your life, and delivers lasting results.Have questions or comments for the podcast? Drop them here - https://forms.gle/AEu5vMKNLDfmc24M7Check out our FREE 4-Week Glute Program - https://go.physiquedevelopment.com/freegluteprogram701788And keep the gains rolling with 12 MORE weeks of glute growth (use code POD at checkout for $25 off!) - https://train.physiquedevelopment.com/workout-plans/963551As always, it is our goal not only to supply you, the listener, with valuable insights on the topics or questions but also to plant some seeds for further research and thought. Be sure to like and subscribe and leave us a review wherever you're listening if you loved this episode!Timestamps:(0:00) Today's topic(1:20) The recovery phase (where a successful muscle-building phase *actually* begins)(5:18) What you can expect during a recovery phase(5:55) Training during the recovery phase(6:30) How long a muscle-building phase should last(7:19) Setting your calories and macros for your build(8:37) Adjustments to training to optimize muscle gain(15:25) How much weight you should gain during a build (and how quickly)(17:11) The most important markers to keep an eye on(22:18) The best way to ensure a successful building phaseFollow us on Instagram:Coach Alex - https://www.instagram.com/alexbush__Coach Sue - https://www.instagram.com/suegainzPhysique Development - https://www.instagram.com/physiquedevelopment_Physique Development Podcast - https://www.instagram.com/physiquedevelopmentpodcast----Produced by: David Margittai | In Post MediaWebsite: https://www.inpostmedia.comEmail: david@inpostmedia.com© 2025, Physique Development LLC. All rights reserved.

In this episode of the Female Health Solution Podcast, I break down one of the biggest frustrations women face: Your labs come back "normal," yet you still feel exhausted, inflamed, moody, or nothing like yourself, and no one can explain why. Here's what we cover: Why basic blood work misses the real problem Regular labs look for disease, not dysfunction. A standard CBC or hormone panel can't show how your hormones are produced, processed, or eliminated. Blood tests catch crises, not the early warning signs of perimenopause, adrenal burnout, or estrogen dominance. What DUTCH urine hormone testing reveals that blood work can't All three estrogens: E1, E2, and E3 Phase 1 and Phase 2 estrogen detox (your liver pathways) Methylation which is a major cause of PMS, migraines, brain fog, and mood swings Cortisol rhythm throughout the day Nutrient deficiencies and gut-related patterns This level of detail finally explains why you feel off and what to do about it. Real client stories Sara's story: Blood labs said "you're fine." Her DUTCH test showed exactly why she had migraines, poor sleep, and terrible PMS. Within months on a targeted plan, PMS dropped by 50 percent and her menstrual migraines disappeared. At her follow-up, her clinic literally told her, "We don't know how to read this." Jenna's story: A mom of five determined not to be a "half version" of herself. She researched every option and realized she would have to piece together three times the number of tests to get what DUTCH shows in one report. Once she saw her results, she finally had a roadmap instead of guessing. Why your hormone issues are never just one thing Your genetics, stress load, pregnancies, environmental toxins, sleep, and nutrient status all intersect. DUTCH shows which pieces are breaking down: production, processing, or elimination, so you stop guessing and start targeting the right areas. Why DUTCH is the roadmap your health has been missing This test shows: Where the "holes in your boat" actually are Which systems need support What is driving your symptoms And exactly what to do next Instead of random supplements, you get clarity. Ready for real answers? If you're tired of hearing "your labs are normal" while your body tells a different story, it's time to go deeper. You can: Order a DUTCH test through us Get a personalized review and plan from my team Finally understand your hormone story and what your body has been trying to tell you Order your hormone test: https://drbethwestie.com/dutch-hormone-testing/

The Big 12 discussing private capital deal with RedBird Capital Partners and Weatherford Capital; Phase 3 of World Cup tickets sees five million requests; the NWSL approves high impact player roster mechanism and Michigan expands athletic department probe. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

At the 2025 American Society of Hematology Annual Meeting & Exposition (ASH), CancerNetwork® sat down with a variety of researchers and clinicians to discuss potential advancements across hematologic oncology care. These experts shared their findings related to investigational therapeutic regimens and strategies that may prove impactful across different multiple myeloma, lymphoma, and leukemia populations. First, Krina K. Patel, MD, MSc, highlighted findings from the phase 2 iMMagine-1 study (NCT05396885) assessing treatment with anitocabtagene autoleucel (anito-cel) among patients with relapsed/refractory multiple myeloma. According to Patel, an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, the novel cellular therapy elicited an overall response rate (ORR) of 96% and a stringent complete response or CR rate of 74% among the evaluable patients. She also discussed how anito-cel's unique mechanism of action may show efficiency compared with other cellular therapy products while reducing the risk of cytokine release syndrome and other delayed toxicities. Next, Manali Kamdar, MD, spoke about data from a long-term follow-up phase 2/3 study (NCT03435796) based on the phase 3 TRANSFORM trial (NCT03575351) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) vs standard-of-care therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL). Long-term follow-up showed that liso-cel continued to elicit improvements in progression-free survival and overall survival across this population. Kamdar, the clinical director of Lymphoma Services at the University of Colorado Anschutz School of Medicine, touched upon the patient subpopulations who are most suitable to receive liso-cel while emphasizing the agent's curative potential in the second-line setting. Finally, Wei Ying Jen, BM BCh, MA, MMed, MRCP, FRCPath, detailed results from the phase 1/2 SAVE trial (NCT05360160), which showed responses with an all-oral combination of revumenib (Revuforj), decitabine/cedazuridine (Inqovi), and venetoclax (Venclexta) for patients with newly diagnosed acute myeloid leukemia. Jen, an assistant professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, noted how an all-oral regimen may offer an “advantage” compared with standard intensive chemotherapy, which requires patients to travel to the hospital to undergo an infusion. References Patel K, Dhakal B, Kaur G, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: updated results from iMMagine-1. Blood. 2025;146(suppl 1):256. doi:10.1182/blood-2025-256 Kamdar M, Solomon S, Arnason J, et al. Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM. Blood. 2025;146(suppl 1):3710. doi.10.1182/blood-2025-3710 Jen WY, DiNardo CD, Short NJ, et al. Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Blood. 2025;146(suppl 1):47. doi:10.1182/blood-2025-47

Welcome to the Psychedelic Conversations Podcast!In this episode of Psychedelic Conversations, we speak with Rotem Petranker, PhD, executive research adviser at Rose Hill, to explore the realities of psilocybin microdosing research. We discuss his Phase 2 clinical trial investigating microdosing psilocybin for major depressive disorder, including study design, safety outcomes, and early findings that challenge some popular assumptions about dose and frequency. Beyond the data, we dive into deeper themes around expectancy, set and setting, and why connection itself may be one of the most powerful healing factors. We also reflect on the limitations of overly medicalized research, the importance of pre-registered science, and how collaboration between scientists, communities, and lived experience can move the field forward with integrity.About Rotem:Rotem graduated with a BsC in psychology from the University of Toronto and an MA in social psychology from York University. His master's thesis modeled the contribution of affective regulation to the relationship between mindfulness and sustained attention. Rotem earned his PhD from McMaster University, working with Dr. David Shore. His dissertation focused on a double-blind, placebo-controlled psilocybin study.Connect with Rotem:- Website: https://www.petranker.com/- LinkedIn: https://ca.linkedin.com/in/rotem-petranker-79838a87Thank you so much for joining us! Psychedelic Conversations Podcast is designed to educate, inform, and expand awareness.For more information, please head over to https://www.psychedelicconversations.comPlease share with your friends or leave a review so that we can reach more people and feel free to join us in our private Facebook group to keep the conversation going. https://www.facebook.com/groups/psychedelicconversationsThis show is for information purposes only, and is not intended to provide mental health or medical advice.About Susan Guner:Susan Guner is a holistic psychotherapist with a mindfulness-based approach grounded in Transpersonal Psychology, focusing on trauma-informed, community-centric processes that offer a broader understanding of human potential and well-being.Connect with Susan:Website: https://www.psychedelicconversations.com/Facebook: http://www.facebook.com/susan.gunerLinkedIn: https://www.linkedin.com/in/susan-guner/Instagram: http://www.instagram.com/susangunerTwitter: http://www.twitter.com/susangunerBlog: https://susanguner.medium.com/Podcast: https://anchor.fm/susan-guner#PsychedelicConversations #SusanGuner #RotemPetranker #PsychedelicPodcast #Microdosing #PsychedelicScience #PsychedelicResearch

Defence ministers from Australia, the United States and the United Kingdom met at the Pentagon for the first Australia-United Kingdom-United States (AUKUS) ministerial discussions, marking a shift towards delivering the trilateral submarine pact. The leaders highlighted regional stability needs, defence capability and the $368-billion project's strategic value, while critics remain concerned over nuclear risk, transparency and Australia's obligations under nuclear-free treaties.

Professor Jan Loffeld, Theologe aus Utrecht, diskutiert sein Buch "Wenn nichts fehlt, wo Gott fehlt", das die religiöse Indifferenz in der modernen Gesellschaft beleuchtet. Er beschreibt die dritte Phase der Säkularisierung als "Apatheismus", gekennzeichnet durch Gleichgültigkeit gegenüber der Gottesfrage, die nicht durch fehlende Argumente, sondern durch konkurrierende Lebenserfüllungsoptionen entsteht. Loffeld argumentiert, dass die Kirche oft versucht hat, sich übermäßig an eine humanistische Gesellschaft anzupassen, wodurch sie ihre unterscheidbare, transzendente Botschaft verlor und überflüssig wurde. Er plädiert dafür, dass die Kirche die Konturen des Evangeliums als alternatives "Counternarrative" klarer hervorhebt und die Souveränität Gottes respektiert. Trotz der Realität einer schrumpfenden Minderheitenkirche sieht er die Zukunft in einer Kirche, die das Evangelium als ihre wichtigste Ressource ernst nimmt. _________________________ Movecast und Lovecast finanzieren sich ausschließlich von Spenden. Wenn du Movecast unterstützen möchtest, findest du alle Informationen hier: https://movecast.de/spenden-givio/. Vielen Dank! Das Transskript zur Folge findet sich ausschließlich auf www.movecast.de unter der jeweiligen Episode. GEMA-freie Musik von www.frametraxx.de Cinematic by Makaih Beats is licensed under a Attribution-NonCommercial-NoDerivatives 4.0 International License. https://creativecommons.org/licenses/by-nc-nd/4.0/deed.de    

The Phase No One Talks About: Slow Rebuild, Nervous System Repair, and Why I Went QuietHey friends, it's Lydia. It's been a little quiet here on the podcast — not because I didn't want to show up, but because my own system needed a pause. My body was asking for space to recalibrate, to integrate, to just be. And as I slowed down, I realized something: the pause itself was a signal — not just for me, but for the people I work with every day.We rarely talk about the phase that comes after crisis, after the acute danger has passed. You're no longer in emergency mode, you feel some relief… but something still feels off. Energy dips, digestion wobbles, micro-flares appear, and your nervous system feels “functional but not free.” This is the Slow Rebuild Phase — the longest, quietest, and most misunderstood stage of healing. And yet, it's where the deepest repair happens.In this episode, I give you a window into what's happening biologically, metabolically, and neurologically during this in-between stage. I explain why your metabolism might feel cautious, why your gut microbes are slow to wake up, and why your nervous system is testing safety every single day. I describe the micro-flares — the subtle digestive shifts, energy crashes, sinus irritations, emotional spikes, or tension patterns — that are actually proof your system is learning to trust itself again.I also talk about why people get stuck here: the urge to push harder, the pressure to see immediate progress, and the challenge of trusting a body that has spent years in survival mode. Most importantly, I share why slowness isn't stagnation — it's strategy. Rebuilding capacity, restoring stability, and cultivating safety in your body takes time, pacing, and gentle, intentional steps.Throughout the episode, I weave in my own recent experience of stepping back from the podcast, reorganizing my business structures, and intentionally moving slowly. It's living proof of what it looks like to honor this phase, to prioritize stability over speed, and to rebuild from a place of nervous system alignment rather than urgency.If you're listening to this and realizing you're in that in-between phase — not in crisis anymore, but not fully restored — this is exactly the phase I support clients through.I work one-on-one using minerals, microbiome data, and nervous system mapping to help your body stabilize, repair, and move forward at the pace it can actually handle.If you want to explore working together, you can find the details HERE. You don't need to do more.You need the right support at the right time.For more on this, check out my blog post, Rebuilding Capacity: The Missing Piece in Chronic Health Recovery, where I go deeper into the biology and practical guidance for navigating this phase. Mineral Foundations Course HERE Minerals and microbes package HERE Rewilded Wellness program HERE Join my newsletter HERE If you are interested in becoming a client and have questions, reach out by emailing me: connect@lydiajoy.me Find me on Instagram : @ Lydiajoy.me OR @ holisticmineralbalancing

In den letzten Jahren dürfte auf diesem Kanal deutlich geworden sein, dass ich kein politischer Scharfmacher bin. Darum geht es mir auch nicht, sondern um Geldanlage. Ich bin allerdings überzeugt, dass wir vor einer außergewöhnlichen Phase stehen, in der sich die Dinge nicht einfach „wieder einruckeln“ und die Märkte anschließend so laufen wie immer. Wir sprechen über Entwicklungen, die mindestens so groß sind wie der KI-Trend, die Energiewende oder die Digitalisierung.
 Unter diesem Text findet ihr ein öffentlich zugängliches Dokument aus dem Weißen Haus: die „National Security Strategy of the United States of America“ vom November 2025. Darin wird sehr klar beschrieben, wie die USA ihre Strategie anlegen – auch im Umgang mit Verbündeten. Ebenso wird deutlich, wer als zentraler Rivale gilt: China. Es wird beschrieben, wie diese Rivalität beziehungsweise dieser Wettbewerb gewonnen werden soll – und das hat erhebliche Konsequenzen für uns als Anleger, aber auch für Europa. Denn wir sind der Gefahr ausgesetzt, zwischen den Fronten zerrieben zu werden, wenn wir keine eigene Strategie entwickeln. Wie also sieht diese Strategie konkret aus, und wie kann ich als Anleger daraus Chancen ableiten? Darüber spreche ich - legen wir los.
 ► Das im Podcast genannte Dokument: https://www.whitehouse.gov/wp-content/uploads/2025/12/2025-National-Security-Strategy.pdf
 ► Hole dir jetzt deinen Zugang zur brandneuen BuyTheDip App! Jetzt anmelden & downloaden: http://buy-the-dip.de
 ► An diese E-Mail-Adresse kannst du mir deine Themen-Wünsche senden: podcast@lars-erichsen.de
 ► Meinen BuyTheDip-Podcast mit Sebastian Hell und Timo Baudzus findet ihr hier: https://buythedip.podigee.io
 ► Schau Dir hier die neue Aktion der Rendite-Spezialisten an: https://www.rendite-spezialisten.de/aktion
 ► TIPP: Sichere Dir wöchentlich meine Tipps zu Gold, Aktien, ETFs & Co. – 100% gratis: https://erichsen-report.de/
 Viel Freude beim Anhören. Über eine Bewertung und einen Kommentar freue ich mich sehr. Jede Bewertung ist wichtig. Denn sie hilft dabei, den Podcast bekannter zu machen. Damit noch mehr Menschen verstehen, wie sie ihr Geld mit Rendite anlegen können.
 ► Mein YouTube-Kanal: http://youtube.com/ErichsenGeld
 ► Folge meinem LinkedIn-Account: https://www.linkedin.com/in/erichsenlars/
 ► Folge mir bei Facebook: https://www.facebook.com/ErichsenGeld/
 ► Folge meinem Instagram-Account: https://www.instagram.com/erichsenlars
 Die verwendete Musik wurde unter www.soundtaxi.net lizenziert. 
Ein wichtiger abschließender Hinweis: Aus rechtlichen Gründen darf ich keine individuelle Einzelberatung geben. Meine geäußerte Meinung stellt keinerlei Aufforderung zum Handeln dar. Sie ist keine Aufforderung zum Kauf oder Verkauf von Wertpapieren.
 Zum Zeitpunkt der Erstellung dieses Beitrags, lagen bei dem Autor, Lars Erichsen, keine Interessenskonflikte vor. Geplante Änderungen: Keine. Weitere Informationen entnehmen Sie bitte unserem Transparenzhinweis zum Umgang mit Interessenskonflikten: https://www.lars-erichsen.de/transparenz-und-rechtshinweis

Syrians are celebrating one year of freedom from the Assad regime, but there are many wounds still to be healed, and the work of transitional justice must now take place. It's a process that links Syria to the US, South Africa and many other countries in between. Ruti Teitel, professor of law at New York Law School and author of "Presidential Visions of Transitional Justice" and Aria Florant, co-founder and CEO of Liberation Ventures, an organization advocating for slavery reparations in the US, join the show.   Also on today's show: Guardian columnist Jonathan Freedland; law school professor Kate Shaw    Learn more about your ad choices. Visit podcastchoices.com/adchoices

Two months have passed since a ceasefire was announced in Gaza, but the second phase of US President Donald Trump's 20-point plan has yet to materialise. The uncertainty has left Gazans anxious that the ceasefire could collapse – as the last truce did in March. The initial part of the agreement included the exchange of Israeli hostages for Palestinian detainees and a stop to the fighting. Now these terms have mostly been met, Israel, Hamas and the mediators cannot seem to agree on how to tackle the next steps. Phase two is supposed to focus on a peacekeeping force and a governing committee, as well as reconstruction in the enclave. But so far there has been much disagreement over which countries will take part in the force and what their mandate will be. Meanwhile, an impasse remains over Israel's withdrawal from Gaza and the disarmament of Hamas. In this episode of Beyond the Headlines, host Nada AlTaher looks at the obstacles that must be overcome to reach the second stage of the ceasefire and what it would take to move the process forward. She speaks to Max Rodenbeck, Israel-Palestine director at International Crisis Group, and to The National's UK bureau chief Damien McElroy.

Hitzewallungen, Hormone und Hirnnebel – in dieser Folge Ladylike nehmen euch Yvonne und Nicole mit auf eine Reise durch die Wechseljahre. Dabei wird nicht nur geschwitzt, sondern auch herzlich gelacht, denn was da mit dem weiblichen Körper passiert, ist manchmal kurios, oft herausfordernd und überraschend befreiend.Nicole spricht offen über Hormon-Chaos, Beckenboden-Baustellen und schlaflose Nächte. Yvonne kontert mit klarer Haltung, viel Feuchtigkeit (noch!) und einer Portion jugendlichem Trotz – noch sei sie schließlich „frisch ausgeblutet“. Zwischen unkontrolliertem Pupsen, Rückenschmerzen und Kackschemeln geht es um mehr als nur Symptome: Es geht um das Selbstbewusstsein, das mit der zweiten Pubertät wächst, um den neuen Blick auf das Leben – und darum, wie viel Kraft und Klarheit Frauen in dieser Phase entwickeln können.Natürlich fehlt auch der gewohnt ehrliche Ladylike-Humor nicht, wenn Gleitcremes, Matcha-Tee und tiefe Hocken auf dem Gesundheitsplan stehen. Was hilft wirklich? Was verändert sich im Bett – und im Kopf? Und was haben eigentlich Walfrauen damit zu tun?Hört einfach rein in die neue Folge und erfahrt, warum die Wechseljahre der Anfang von etwas richtig Gutem sein können.Habt Ihr selbst erotische Erfahrungen, eine Frage oder Story, über die Yvonne & Nicole im Ladylike-Podcast sprechen sollen? Dann schreibt uns gern an @ladylike.show auf Instagram oder kontaktiert uns über unsere Internetseite ladylike.showHört in die Folgen bei RTL+, iTunes oder Spotify rein und schreibt uns gerne eine Bewertung. Außerdem könnt ihr unseren Podcast unterstützen, indem ihr die neuen Folgen auf Euren Kanälen pusht und Euren Freunden davon erzählt.Erotik, S**, Liebe, Freundschaft und die besten Geschichten aus der Ladylike-Community gibt es auch im Buch zum Podcast „Da kann ja jede kommen“! Hier geht's zum Buch: bit.ly/ladylike-buchUnsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

André Schürrle spricht über die große Frage nach dem Karriereende: Wie finde ich mich selbst, wenn ich nicht mehr der Fußballer bin? Er beschreibt die schwierige Phase, in der er allen Angeboten (auch lukrativen) Nein sagen musste, um herauszufinden, was er wirklich will – und warum „Nichts tun“ am Ende keine Erfüllung bringt. Was du lernst: Warum Selbstfindung nach dem Karrierehöhepunkt so schwer ist Wie du lernst, radikal „Nein“ zu sagen, um „Ja“ zu dir selbst zu sagen Warum der Weg aus der Identität als Leistungsträger so lange dauert Weshalb „Nichts tun“ auf Dauer keinen Sinn stiftet – auch mit finanzieller Freiheit ALLES ZU UNICORN BAKERY: https://stan.store/fabiantausch   Mehr zu André: Instagram: https://www.instagram.com/andreschuerrle/  DRYLL: https://www.dryll.co/  Die ganze Folge Selbst & Frei findest du hier: YouTube: https://youtu.be/y6DdioC6APA?si=udLkb3Q6Er9mAR2D  Spotify: https://open.spotify.com/episode/3YZEohw6ZDRNnKsibnxJyh?si=71d2cfc2b5e84230  Apple: https://podcasts.apple.com/de/podcast/nach-dem-wm-titel-alles-hinschmei%C3%9Fen-andr%C3%A9-sch%C3%BCrrle/id1846867704?i=1000736687080 Join our Founder Tactics Newsletter: 2x die Woche bekommst du die Taktiken der besten Gründer der Welt direkt ins Postfach: https://www.tactics.unicornbakery.de/

Join for a live in person event in Newark New Jersey on February 27 through March 1st https://www.brianscottlive.com/february-2026 Join The Reality Revolution Tribe

When President Trump took office in January, Congress seemed poised to play a supporting role in the story of Trump's second term. Republicans largely fell in line to support President Trump's cabinet nominees and much of his broader agenda; it's been reported that Trump himself has joked that he's both the President and Speaker of the House. Congressional Democrats, meanwhile, appeared helpless to mount a vigorous opposition to Trump's policies, or even to energize their own base. But this fall, those dynamics began to shift. Congressional Republicans have stood up to Trump on some key issues, including most notably the release of files related to the Jeffrey Epstein case. And Congressional Democrats galvanized supporters around this fall's government shutdown fight over the future of ACA health insurance subsidies.On this episode, two experts on Congressional politics spoke with Dan Richards about the shifting role of Congress in U.S. politics, as President Trump enters his “lame duck” phase and America gears up for a midterm election in less than 12 months. They also discuss Congress's consistently low approval rating among Americans, and explore what (if anything) could be done to make Congress work better under the Trump administration and beyond. Guests on this episode: Eric Patashnik is a political scientist and director of the Watson School's Taubman Center for American Politics and Policy. Congresswoman Kathy Manning represented North Carolina's sixth district from 2020 to 2024 and is currently a senior fellow in international and public affairs at the Watson School.

Starcloud has successfully trained and run the first large AI model in space. DARPA has awarded BAE a Phase 2 contract to advance autonomous space-based surveillance. Firefly Aerospace will host Volta Space Technologies' wireless power receiver on Firefly's Blue Ghost Mission 2 lander on the far side of the Moon, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Jerome Hittle, CEO & Founder at AmplifiedSpace. You can connect with Jerome on LinkedIn, and learn more about AmplifiedSpace on their website. Selected Reading ‘Greetings, earthlings': Nvidia-backed Starcloud trains first AI model in space as orbital data center race heats up BAE Systems to advance autonomous space-based surveillance technology for DARPA Firefly Aerospace Adds Volta's Wireless Power Receiver to Blue Ghost Mission on Far Side of the Moon HawkEye 360 and International Partner Establish Multi-Year Data Access Agreement ESA - Space-enabled air traffic control takes flight globally Momentus Selected for U.S. Space Force SHIELD Contract Vehicle Bezos and Musk Race to Bring Data Centers to Space NASA Teams Work MAVEN Spacecraft Signal Loss Share your feedback. What do you think about T-Minus Space Daily? Please take a few minutes to share your thoughts with us by completing our brief listener survey. Thank you for helping us continue to improve our show.  Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

Au programme de Radio foot aujourd'hui (16h10 / 21h10 T.U) : - La Ligue des Champions. Nous revenons sur la 6è journée de phase de Ligue. ; Nous faisons le point sur le classement, dominé par Arsenal qui a poursuivi son carton plein. ; J-10 avant la CAN. Ligue des Champions Nous revenons sur la 6è journée de phase de Ligue. - Real Madrid 1 - 2 Manchester CityRetour sur le choc de la semaine et la nouvelle défaite des Merengue, privés de Kylian Mbappé. - Athletic Bilbao 0 - 0 Paris SGDominateurs, les champions d'Europe en titre ont buté sur la défense basque. Ils restent bien installés dans le top 8. - Nous faisons le point sur le classement, dominé par Arsenal qui a poursuivi son carton plein. Qui finira dans le top 8 et accédera aux huitièmes de finale ? Qui passera par les barrages ? Nous nous projetons sur les deux dernières journées de la phase de ligue. J-10 avant la CAN !  Début de la série du service des sports de RFI consacrée aux joueurs de Ligue 1 qui s'apprêtent à participer à la Coupe d'Afrique des Nations au Maroc. Aujourd'hui, entretien de Baptiste Leduc avec Lionel Mpasi, le gardien des Léopards de RDC. Autour d'Olivier Pron ce jeudi : Patrick Juillard, Salim Baungally et Yoro Mangara. Laurent Salerno aux manettes, Victor Missistrano à la préparation.

Phase one of Donald Trump's ceasefire in Gaza appears to be holding, but it's precarious as hundreds of Gazans have been killed since it began and hundreds of thousands remain homeless and displaced.The Israeli defence force still occupies much of the territory and Hamas have re-established themselves in some areas.So is phase two - with its transitional authority and international peace force looking any way possible?Benjamin Netanyahu says it's close, but what's the view of the Palestinians?One person who has reflected their concerns since the current conflict began is Francesca Albanese, the UN's special rapporteur on the Palestinian territories. She has been an outspoken critic of Israel's actions in Gaza, accusing the government of genocide. It's made her powerful enemies including the Trump administration who have sanctioned her while the Israeli government accuse her of bias and have designated her persona non grata.She joined Krishnan Guru Murthy for this episode of The Fourcast.

Au programme de Radio foot aujourd'hui (16h10 / 21h10 T.U) : - La Ligue des Champions. Nous revenons sur la 6è journée de phase de Ligue. ; Nous faisons le point sur le classement, dominé par Arsenal qui a poursuivi son carton plein. ; J-10 avant la CAN. Ligue des Champions Nous revenons sur la 6è journée de phase de Ligue. - Real Madrid 1 - 2 Manchester CityRetour sur le choc de la semaine et la nouvelle défaite des Merengue, privés de Kylian Mbappé. - Athletic Bilbao 0 - 0 Paris SGDominateurs, les champions d'Europe en titre ont buté sur la défense basque. Ils restent bien installés dans le top 8. - Nous faisons le point sur le classement, dominé par Arsenal qui a poursuivi son carton plein. Qui finira dans le top 8 et accédera aux huitièmes de finale ? Qui passera par les barrages ? Nous nous projetons sur les deux dernières journées de la phase de ligue. J-10 avant la CAN !  Début de la série du service des sports de RFI consacrée aux joueurs de Ligue 1 qui s'apprêtent à participer à la Coupe d'Afrique des Nations au Maroc. Aujourd'hui, entretien de Baptiste Leduc avec Lionel Mpasi, le gardien des Léopards de RDC. Autour d'Olivier Pron ce jeudi : Patrick Juillard, Salim Baungally et Yoro Mangara. Laurent Salerno aux manettes, Victor Missistrano à la préparation.

We discuss promising Phase 2 results from Nanoscope regarding the use of optogenetics for treatment of retinal degenerations with Allen Ho, MD, Professor of Ophthalmology, Wills Eye Hospital.

In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly's investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis. Highlights: Up to 28.7% weight loss (~71 lbs) over 68 weeks 75% reduction in knee pain and major improvements in physical function Cardiometabolic benefits: lower triglycerides, non-HDL cholesterol, hsCRP, and blood pressure We also cover Common side effects and safety signals Perceived excessive weight loss — and what this means for clinical practice in a new era of powerful medications A reality check on Canadian availability (likely 3+ years away) A strong warning about illegal online sales and the risks of buying unregulated products A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-dynamic landscape of these industries, recent advancements have underscored both the scientific ingenuity and strategic foresight shaping patient care today.Pfizer has unveiled promising clinical trial data for Tukysa, indicating its potential as a first-line maintenance therapy in HER2-positive breast cancer. This development suggests that Tukysa could delay disease progression, offering patients extended survival prospects and an improved quality of life. Additionally, Pfizer's recent licensing agreement with Yaopharma for YP05002—a small molecule GLP-1 agonist currently in Phase 1 trials aimed at obesity treatment—highlights their strategic push into the rapidly evolving obesity treatment market.Meanwhile, Fondazione Telethon, an Italian nonprofit organization, has achieved a significant milestone with FDA approval for Waskyra—the first gene therapy for Wiskott-Aldrich syndrome. This ex vivo gene therapy directly targets the genetic roots of this rare disease, shifting treatment from symptomatic management to addressing underlying causes. This approval is transformative not only for patients suffering from this condition but also for the broader field of gene therapies, heralding a new era in treating rare genetic disorders.On the strategic front, Eli Lilly's decision to establish a $6 billion active pharmaceutical ingredient manufacturing facility in Huntsville, Alabama, marks a pivotal investment in U.S. manufacturing capabilities. This site will be critical in producing APIs for small molecule and peptide medicines, a testament to Lilly's commitment to meeting growing therapeutic demands while bolstering domestic production resilience—a trend gaining momentum across the industry. In oncology, Eli Lilly's Jaypirca demonstrated an impressive reduction in disease progression during Phase 3 trials for chronic lymphocytic leukemia.Biocon's acquisition of Viatris' stake in their biosimilar subsidiary exemplifies the shifting dynamics within the biosimilars market. This move allows Biocon to consolidate its market position as biosimilars gain traction as cost-effective alternatives to branded biologics. Such strategic realignments are indicative of competitive maneuvering aimed at capturing greater market share and driving down healthcare costs.Roche has made strides with compelling results from its Phase 3 trial of giredestrant, an oral selective estrogen receptor degrader showing a 30% reduction in risk for invasive breast cancer recurrence or death. The significance of this development lies in offering an oral alternative to injectable treatments, potentially improving patient adherence and reshaping standard care protocols for hormone receptor-positive breast cancer. Furthermore, Roche has achieved another regulatory milestone with its monoclonal antibody Gazyvaro gaining EU approval for treating lupus nephritis following successful Phase 3 trials.Innovation continues unabated as Formation Bio forms a new subsidiary through a $605 million deal with Lynk Pharmaceuticals. By securing rights to a next-generation immunology asset, Formation Bio positions itself at the forefront of immunological research developments. Concurrently, BioNTech and Bristol Myers Squibb have reported positive results from Phase 2 trials of Pumitamig for triple-negative breast cancer—validating bispecific antibodies' efficacy within oncology.Collaborative efforts are also reshaping industry landscapes. Bora and Corealis have partnered to create an end-to-end contract development and manufacturing organization for oral solid dose drug development. This collaboration aims to streamline processes and provide scalable solutions through a single contracting source, reflecting a shift towards integrated service models that enhance efficiencySupport the show

5pm: In Studio Guest – Chris “Sully” Sullivan – Kiro Traffic Guru // Light rail over I-90 to start final phase of testing // Spokane woman charged with harassment for threatening Brandi Kruse over initiatives // Letters

Israel is on edge again as three political shockwaves collide: Itamar Ben‑Gvir ignites global outrage by wearing a yellow noose pin in the Knesset debate over the death penalty for terrorists; Hamas kingpin Khaled Mashaal resurfaces in Istanbul with a chilling vow to eliminate Israel and reject any Trump‑brokered plan; and President Trump prepares to host Prime Minister Netanyahu at Mar‑a‑Lago to force momentum on “Phase 2” of his Gaza blueprint.

Olympiacos stressed us out today after missing boatloads of chances in what should have been a 3 or 4-0 win. In the end we get the 3 points and that's what matters. Ari dissects the win and discusses what comes next!

Have a question you want answered on the podcast? Send us a text!Enjoy this free training to learn why Emotional Brain Training is essential for long-term results. Plus, we just added 3 powerful bonuses to Zivli that dramatically increase the level of support you'll receive. Enroll today at https://zivli.com/join. 

Jennifer Keeley and Mary Whittenhall, experienced nurse practitioners in the field of pulmonary hypertension, discuss the management of cough in patients receiving inhaled therapies for pulmonary hypertension and interstitial lung disease. #GossamerBioPartner #sponsored This Special Edition episode is sponsored by Gossamer Bio. Jennifer Keeley, DPN: My name's Jennifer Keeley. I'm a nurse practitioner and I practice in a large academic institution in Pittsburgh, Pennsylvania, Allegheny Health Network, specifically Allegheny General Hospital. I am a nurse practitioner there and have been in the clinic over 10 years, and in the PH space as a nurse practitioner for over 15 years, as a registered nurse for almost 20 years. So, I have a lot of experience and I'm really excited to be here today to talk about inhaled therapies and cough. Mary Whittenhall, MSN: My name is Mary Whittenhall. I'm also a nurse practitioner. I am currently an advanced practice provider at Pulmonary and Sleep Associates in East Providence, Rhode Island. I've been in pulmonary hypertension for about 11 years now. In that time, I have worked in a variety of settings, both inpatient and outpatient, managing patients with pulmonary vascular disease, and have also touched upon patients with interstitial lung disease and pulmonary hypertension.  I get very excited when I hear about new opportunities for our PH patients. I think a lot about even when I started in pulmonary hypertension and the therapies that were available to our patients. Many of these therapies had been around for a little bit of time. But also something that I think is extremely exciting is that there's just been a rapid progression in development of therapies. And now, with the focus of looking at these therapies as potentially disease modifying, not necessarily slowing the progression of disease. With the advent of all of these new therapies, there become more options for our patients, as well. Often, patients can't tolerate some of the medications that we have due to side effects and despite lots of work to manage these side effects, the patients are not always successful. One of the great things being involved in an academic center is that we have the ability to help link patients to cutting edge research, particularly looking at a new drug that is an inhaled therapy that has shown significant promise in improving the lives of patients with pulmonary hypertension. As a part of the PH community, we all do quite a bit of networking with each other, as well as with our patients and other colleagues in the space. In that time, we did network regarding the study and have participated in some activities where we're looking at the data from the Phase 2 part of this trial and then also looking at some of the side effect management related to the medication, which seemingly is well tolerated. However, for some patients it may not come extremely easy. I think that's where the role of the nurse or the advanced practice provider really comes in this space is that we have a real strong dedication to helping educate patients about ways to manage these side effects. We want patients to be able to continue with therapies. We don't want them to say, "Well, this isn't working for me, it's time to move on." I think that we have a lot of strategies and a lot of experience with trying to help patients really figure out the best way to manage these things and to be confident that they can continue on with obviously the biggest benefit of improving their pulmonary vascular disease. Jennifer Keeley, DPN: We actually met at an advisory board last year. It was an advisory board consistent of registered nurses and nurse practitioners who, just like Mary and myself, have vast experience with patients and therapies, not just in the inhaled space, but more conventional pulmonary vasodilator medications that have been used in our patients for many, many years. As Mary had suggested before, when we start to think about newer agents, many, many of them are not the conventional pulmonary vasodilator medications, but disease modifying agents. Now, we've acquired an armamentarium of medications. So, inhaled delivery is just a really great option to avoid systemic side effects on top of each other. Our PH patients today, many of them are on more than three therapies, many of them are on four or even more therapies, so the delivery of the medication is just one aspect. When we talk about cough and side effects, I like to think about it and explain to my patient when we talk about side effects, particularly cough, to imagine a Venn diagram with cough being in the middle and what affects cough. You see this outward circle, how we deliver it, what kind of device we deliver it in. The drug, how small, large are the particle size? Is it easy enough to use for our patients? The formulation, is it dry powdered versus inhaled aerosolized? And then finally, just the patient themselves. What's their background? What type of PAH do they have? So, we can talk a little bit more about this, but just to get us started, this is how this developed and we had a lovely advisory board meeting with seralutinib and Gossamer Bio, and this was the outcome of it. We produced a lovely poster. This is a conversation if you will, that Mary and I are going to have based on what we talked about and the poster production, that came out of that wonderful advisory board. Mary Whittenhall, MSN: Inhaled therapies are unique in a way in that they actually have direct access to the lungs. So, when you think of an oral medication, an oral medication needs to be digested in the gut and sometimes that systemic digestion takes a while. Additionally, it's also often that we see patients that have more systemic side effects when we're using an oral formulation. Intravenous or subcutaneous formulations of these medications tend to cause pretty strong systemic side effects for patients, and there tends to be a lot of management that we need to do to help make these side effects more tolerable. For most of our patients, I say to them, "You're going to think I'm cruel because I don't really want these side effects to go away." In a way, we look at them almost as if you have a cup and your cup is full of water and after the top of the water hits the rim of the cup, then the water starts to spill over onto the sides of the cup. I think of other medications that we typically prescribe for patients in that way that when we get that spill over, so to speak, it's an indication that we've actually targeted all of those receptors that we want to help with vasodilation. Now that we're looking at other medications that don't really necessarily look at vasodilation, we're looking more at treating the blood vessels in a different way or affecting the process for which those blood vessels become diseased. I think that the side effects become different and I think they become less. In working with inhaled therapies, as you can imagine, the number one side effect that most patients will complain of is cough. Sometimes we have patients who have an underlying cough already, and that's usually not related to PAH, but in PH-ILD where we now have an FDA indication to use another inhaled therapy, we've seen in treating these patients that baseline cough is something that is extremely problematic for them before they even start therapies. So, trying to find ways to improve that baseline cough, treat any underlying symptoms, things like acid reflux as well, that may cause that, treating seasonal allergies, et cetera, and then, obviously, managing any additional overlapping side effects that may occur because of the new therapy that they're on. Jennifer Keeley, DPN: I think that's a really important part, is to talk with the patient, educate the patient on these inhaled therapies. First and foremost, that cough is almost an expected side effect. These are patients particularly with our interstitial lung disease patients that have PAH, cough is a part of their daily life. It's important to document and ascertain what these patients' baseline cough is. In many, many clinics, particularly pulmonary PAH clinics, and I'm sure much like Mary's, many of my colleagues have recommended using validated cough questionnaires so that we can get a really, really good baseline of what that patient's baseline cough is. Are you coughing at night? Do you have mucus? How long have you been coughing? Does it interfere with the quality of your life? Do you cough at night? Does it keep you up? Does it interrupt your sleep? Those kinds of things that help differentiate acute cough versus chronic cough. Many of these patients cough every day. They also have other inhaled therapies such as our ILD patients that are also on corticosteroids, many of them on inhaled corticosteroid therapy that can thin the oral pharynx, the posterior pharynx, and really affect the degree of nerve innervation in the posterior pharynx in the mouth. So, just really understanding what the patient's baseline cough is and educating them on the fact that cough is likely going to be a side effect with the use of this inhaled therapy. Certainly, as we continue to use the therapy, we would hope that the cough can be mitigated either through some lifestyle modifications, some natural remedies, and even some medical remedies such as bronchodilators. But really teaching the patient about the medication and inherently that this is likely going to induce a cough, but that we have mitigation strategies to help dissipate the cough. I always like to tell my patients also in the clinical trials, particularly the Phase 2 clinical trials that are out there that patients had a lot of cough. The patients on drug that were in most of the Phase 2 clinical trials for seralutinib and even for treprostinil inhaled, 30 to 40% of them experienced cough. But at the same token, the placebo-based patients that did not receive drug in these Phase 2 clinical trials also had a lot of cough. So, what that's telling you is yes, you're going to get probably some more cough, but it's likely not going to be that much or more far advanced than the cough that you're already experiencing. I also think it's important to tell these patients, many, many patients that experienced cough did not stop the medication. Actually, in these Phase 2 clinical trials, very few stop the medication. So, that gives you a really good big picture that we are pretty good at educating our patients how to mitigate cough, and if we aren't, then we should learn how to do so. Mary Whittenhall, MSN: I think it's important for us to set some expectations for patients when we're talking about cough. We've already discussed a bit that cough can happen for people from other things outside of their lung disease, but it's important to also look at what may be causing the cough when we are giving a patient an inhaled therapy. So, any type of inhaled therapy, whether that be a dry powder, a mist, whether that's nebulized or through in actuated inhaler, there are particles inside of that medication as it's going in and those little particles, when your lungs inhale that medication, those particles are penetrating your lungs and your lungs are not accustomed to them being there. It's almost as if your lungs are saying, "I don't recognize this. I don't know why this is here," and it may feel like it's an irritant, so you may start coughing as a result of that, but the cough is not necessarily a bad thing. Those particles are there, and the job is to essentially help deliver the medicine to penetrate that lung tissue and then for your body then to absorb the medicine. Your airways and your blood vessels inside of your lungs are extremely close to each other. So, when you inhale that medication, those little blood vessels are also right next to where those airways are, and then that is how those blood vessels then absorb that medication, because they're so close to the site at which those particles come into your lungs. Jennifer Keeley, DPN: I think this is an important concept to understand. They choose the form of delivery based on the goal of delivering the most medication efficiently to the distal bronchioles. That's where the disease is. It's in the distal arteries. So, trying to formulate how we get these very powerful, oftentimes disease modifying agents into the periphery of the lungs can be very challenging. Dry powdered inhaler is one form that the variability of delivery is not as dispersed as an aerosolized. So, it's more efficient delivery to the place where the medication needs to work the best, and that's in the distal periphery of the lungs. Unfortunately, one thing you have to deal with is that oftentimes these medications, dry powdered medications, not just in the PH space, but there's a lot of other dry powdered inhalers in the COPD space, as well. Oftentimes, what happens is these powdered particles get dispersed extra thoracically. So, they get dispersed in the oral mucosa, in the posterior pharynx, on the way down into the stomach. That's wherein we have to deal with mitigating side effects. The biggest side effect of these particles, even though they're very small, is cough. So, technique comes into play. Mitigating things to coat the posterior pharynx come into play. Re-education comes into play. Show me again how you're doing this inhalation, because I don't think that you're holding this okay. In one instance, I had a patient that was inhaling dry powdered inhaler with the medication right out of the refrigerator. So, the medication was cold. It was clumping at the back of her throat. All of these things really take into consideration how we most efficiently get the medicine to these pulmonary arterial hypertension patients where their disease is oftentimes very difficult to get to, and other forms of medications that are systemic, orals, parenterals that have first pass metabolism, and so you're going to get more side effects from those medications. So, I always teach my patients, "Hey, we're a couple steps ahead because we're bypassing the type of metabolism that you get with orals and even parenterals." Mary Whittenhall, MSN: There are so many challenges that these patients face. Oftentimes, patients have never been sick before they develop this, and now we're putting them on multiple therapies, multiple modalities, telling them that there's going to be side effects and they need to learn how to manage them. It's certainly a lot to handle. But I think one of the best things that we have in our PH community is that we really work so hard to partner with the patients and their loved ones and forming this relationship, fostering that relationship as time goes on, I believe that these patients really do trust us and that what we're telling them is things are going to be okay. We are going to be there by your side. We're not going to give you this medicine and then say, "See you in six months. Hope everything goes well." We're really going to be working with them. In some cases in my specialty clinic, we have nurses, we have a pharmacist, a pharmacy tech, and then our advanced practice providers that check in with these patients quite regularly. We are actually taking the initiative to reach out to them versus the patient who may be having trouble advocating for themselves or feeling like, "Really, I don't want to be a pain, but this is challenging for me." We are really in touch with them, and that connection also helps to keep patients on therapy. So, what are some of the specific techniques to manage or mitigate cough? This is something that was a real hot topic at our last advisory meeting. We put together a bunch of folks in the room who deal with other inhaled therapies and patients that have cough and said, "Well, what do you tell patients to do?" First and foremost is to look at any other potentially underlying conditions that may be causing cough and ensure that treatment of those underlying conditions is optimized. I think cough is actually the number one referral for any type of pulmonary practice, but it is a really, really broad differential when it comes down to it. We obviously look first at things like environmental factors. If this could be seasonal allergies, then we try treating patients with antihistamines. Perhaps some of those are intranasal, as well, that may help with some things like rhinorrhea or post nasal drip. Acid reflux is actually a huge, huge reason for cough. Many patients say, 'Well, I don't get acid reflux. I don't feel that burning in my chest after I eat," but come to find out that it can actually be a silent trigger. So, treating patients with medicines that help to reduce acid or suppress acid will oftentimes help with that cough. On top of that, when we're dealing with patients that are on inhalers and now we're adding another inhaled therapy. I find that for some patients that are on actual inhalers that sometimes they do better with nebulized treatments. The nebulized treatments are slower, and may have a bit of a better penetration into the lungs and the patients tend to like it. It is one of those things that you do need to be compliant with in order to really see the benefits to it. I will say that oftentimes, again, partnering with the patient, giving them specific instructions about how to do all of this, we can really see some improvement to those symptoms. Then, there's just basic over-the counter measures and precautions, things like making sure that when you're eating that you're not laying down at least for 60 minutes after you've been eating. If you do have acid reflux, trying to sleep with two pillows or a wedge pillow, that can help to keep the head of your bed elevated. Some of our patients have those really fancy adjustable beds that are also quite helpful for that. I think that sometimes things like basic cough drops actually can be quite wonderful and helpful. Drinking very cold or very warm water or tea, adding some honey to that if a patient isn't diabetic, things like that tend to really help with cough. We reinforce these measures when we start therapies like this. Jennifer Keeley, DPN: In terms of mitigation, I think it's really important on technique. This is why, as Mary had alluded to, it's so important to follow up closely with these patients, particularly our elderly patients who sometimes don't, if they have connective tissue disease or scleroderma, have a lot of good fine motor coordination. A couple of things that I wanted to touch on with regards to that… One, these inhalers are typically high resistance, low flow. So, these are not the type of patients that need to be taking in very forceful inhalations with these inhalers and thank goodness, because we're talking about patients that have inflammatory interstitial lung disease, as well as pulmonary vascular disease. So their degree of inspiratory effort is actually minimal to disperse that medication to the distal pulmonary bronchials. It's equivalent to them taking a deep breath in when you ask them to auscultate their lungs. So it's not a big forceful breath. The other thing is too, a lot of times, sometimes more variability in the disbursement of the drug is better in compliance with some patients. Dry-powdered inhalers, again, do not take a very big forceful effort, but some of them, because they are powder, some of the medication will actually hit the back of the throat as it goes down and can cause some irritation, whereas the nebulized form does have a variability in disbursement and can be more easily tolerated in some. The other issue is the technique itself. Oftentimes, we ask them in some of the inhaled therapies to lower the device itself so that the tongue doesn't protrude and get in the way, because if medication gets on the tongue, the next swallow that they take, that medication is going to hit their posterior pharynx, and they're going to probably cough pretty aggressively. I always start off by telling my patients, "Cough is not a bad thing. It's actually a protective reflex and it's involuntary. So, if you cough, don't actually negate it. Don't think it's a bad thing." It's actually a very protective mechanism that avoids irritation in most of our patients probably already irritated mucosa. So, that's how I like to start the conversation. There's so many good techniques that we can share with them over time, and I might add that each patient is different. Each patient needs to have a personalized plan. When we talk about giving patients warm tea, typically chamomile, chamomile tea in itself is anti-inflammatory. Then, when you add something like honey, which is also a soothing, anti-inflammatory natural remedy, you have to really think to yourself, "They're getting honey. If they're diabetic, we don't want to give them too much honey." But, you have to make sure that their swallowing technique is good. There's no aspiration there, particularly if we give them cough drops. Then, just simple things that actually numb or anesthetize the back of the throat are very, very helpful for elderly patients who do have very friable tissue and mucosa from previous therapies like inhaled corticosteroids, as I had talked about before. Dairy products, I tend to ask my patients to avoid those. They can produce a lot of mucus, which these coughs that we see in our inhaled therapy patients are typically tend to be dry coughs, but some patients that have concomitant asthma, COPD, along with their ILD that are using these inhaled therapies can actually have more of a congested mucoid cough. So, avoiding dairy before and after use is always very smart. Avoiding alcohol, avoiding acidic drinks like orange juice, also very, very helpful. Mary Whittenhall, MSN: The part about technique I think is so, so important here. Oftentimes, when patients start these therapies, when they are approved in that space, the specialty pharmacy has a nurse educator that will come out to the patient's home and provide education not only about the medication, but about the administration of that medication. In many cases, the patients will take their first dose while the nurse is present so that the nurse can then critique whether or not the patient took it appropriately and how they tolerated it. I'm going to give a shout out to our nurse educators from the specialty pharmacies, because they are also a really crucial set of eyes and ears for us out in the community. They do provide education to the patients in the home. We have had situations where the patient has done well while the nurse is there, and then two weeks later we get a call from the patient saying, "I can't do this. This isn't working for me." And I'll say, "Okay. Well, you have a couple options. We can have you come in to the clinic and I want you to bring your device with you, and I would like to watch you do a treatment, or I can have the nurse come out and see you again and go over that." And they'll say, "I already know what I'm doing. I don't need that." But in many instances, we have found that they have adjusted their technique. They might've gotten into some bad habit since the nurse has left them. So, really reinforcing that is important. The other thing that I wanted to bring up is that some of our patients with connective tissue disease also have thickness in their tongues. So, their tongues become thicker and more sclerotome as their connective tissue disease progresses. For some of those patients, it is actually hard for them to get their tongue flat enough so that they can get the medication down into their lungs. So, working with those patients to find strategies to help rectify that. I will say that it is not impossible, it just takes maybe a little extra work. Jennifer Keeley, DPN: Inhaled therapies in themselves are pretty portable. Mary had alluded to a little bit earlier, our patients with pulmonary vascular disease, PAH, that are on parenteral therapies, delivering the conventional pulmonary vasodilator therapies. As we get into the new disease modifying agents such as seralutinib, which are anti-fibrotic, anti-inflammatory, anti-prolific medications, these are portable therapies that are actually modifying the disease. So they're portable. They're easy to use. They're easy to use for our patients, again, that are elderly or are younger and are still working, they have a professional life, they don't have to wear a pump that's 24/7 oftentimes. They can use these inhaled therapies first to see if they can avoid parenteral therapy with prostacyclins. Their quality of life is improved immensely. When you can take an inhaled therapy two to four times a day and really improve quality of life, decrease cough, decrease dyspnea, or shortness of breath on exertion. Sometimes, these patients that do very, very well can actually reduce their supplemental oxygen needs. Just improving their walk distances without having to stop or have excessive dyspnea, improves their quality of life. More time spent with loved ones and more time spent in social environments rather than sitting at home. These wonderful inhaled portable therapies have significantly changed our patients' lives and improved their quality of lives. Mary Whittenhall, MSN: This community I think is phenomenal. It's made up of so many great people. There are many patients who have been a part of this space for a long time who really want to help other patients who may be newer to the journey than them. I'm a big advocate for support groups. We've had an extremely active support group in our area for a long time, and I often partner some of my patients that have been with me for quite some time with some of the new patients that may need a bit more help. I can tell them things and my colleagues can tell them things. Oftentimes, the same message doesn't resonate. It resonates differently, I think when it comes from a peer, a patient who may have experienced the same thing as them. One of the things that I really try to drive home with our patients is just that sense of empowerment. Connect with these other folks in the community. They want to help you. They remember what it feels like being newly diagnosed or starting a new therapy or transitioning from another therapy. What that change is like. One of the other things I tell my patients is that we all sit at the same table. I'm not better than you. Maybe I have this information, but this information is for you. It's for you to take and to improve your life. If that information doesn't work for you, then you come back to me with some feedback and we come up with something else that's going to be more helpful to you. I really think having an equal playing field with them and having a very open and honest dialogue is what is going to help our patients do the best. If patients don't feel comfortable reaching out to other local patients or connecting with an in-person support group, there are tons of online resources through the PHA, through phaware®, Team Phenomenal Hope, lots of great groups out there that do things virtually. I think in some ways for some patients, anonymity is important, so being able to protect that is an option for them, but to be able to still get what they need so they can become the best advocate for themselves that they can. Jennifer Keeley, DPN: I stress so importantly to my patients, we are here today in this great environment and we have the armamentarium of medications to treat because of patients just like you that have contributed to the science of the disease and implemented themselves and engaged in these clinical trials. Right now we have an ongoing clinical trial for seralutinib called PROSERA, that's enrolling as we speak. Patients are the best advocates, not only for themselves, but for other patients, and they talk. There's a lot of social media out there where patients communicate amongst themselves and they say, "Through the help of my provider and through the help of my family, I was hesitant to start this additional therapy." They do have, at this juncture, and I don't think it's such a bad thing, they do have a little bit of a pharmacy burden now. Again, these aren't our patients that are on one or two therapies. They're on four or more oftentimes. When you take in our ILD patients, they're also on disease modifying agents, as well, for their interstitial lung disease. So again, I think it's really important for patients to communicate amongst themselves and share their ups and downs in the disease, but also share the rewards that come with surviving and living with PAH. I think one thing that we really do have to understand though is like many other chronic diseases, PH is a personalized disease. You need to have a personalized approach for your patients. That's why it's so very important to do a really good history of your patients and understand not only what their baseline cough is, but who they are, what their personal history is. Are they working? Who's helping to care for them? Who's helping to make that chamomile tea with honey? Who's going to the store to get that? A personalized approach is so important for these patients, I can't stress that enough. Mary Whittenhall, MSN: Special thanks to everybody involved in this project. This was extremely exciting. To my co-podcaster, Jennifer Keeley, who is amazing, and all of us in the PH community are extremely lucky to have her. We are all aware that you are all rare, and we are grateful to be able to help you in this journey. Jennifer Keeley, DPN: Thank you so much, Mary, and what a pleasure it's been to speak with you about cough and inhaled therapies, and thank you to Gossamer Bio for this opportunity and for the opportunity that led to this podcast, which was a significant advisory board amongst specialists in our field, advanced practice providers and registered nurses who were able to convene in a great open space and talk about this. I think this moves our science forward. It helps us to talk about the disease and take better care of our patients. Again, my name is Jennifer Keeley. It's been such a pleasure to deal with my good friend Mary Whittenhall today, and we're aware that our patients are very rare. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on instagram, facebook and x.com @phaware. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @GossamerBio @AHNtoday

Hey my loves, it's Shay, your Love Diva, and today we're getting into something real — the Pull Away Phase. You know that moment when everything feels good, the connection is growing, and then boom… they start acting different. Less calls, slower texts, more distance, and you're sitting there trying not to overthink yourself into a stress nap. In this episode, I'm teaching you what the pull away phase really is, why it happens, and how to respond like a woman (or man) who knows their worth. We're talking about the biggest mistake people make — chasing — and what to do instead so you stay grounded, confident, and emotionally in control. Because baby… if they wobble, you don't collapse. Press play and let your Love Diva walk you through it.

Interview with Allan Ritchie, Executive Chairman & CEO and David Ward, Managing Director of Adavale ResourcesRecording date: 9th December 2025Adavale Resources Limited (ASX: ADD) has emerged as a compelling Australian gold story, having transformed a A$900,000 acquisition into a 115,000-ounce JORC resource at the London-Victoria project in just nine months. The former BHP gold mine in New South Wales' prolific Lachlan Fold Belt is now the focus of an aggressive exploration and development program led by a management team with significant skin in the game.Executive Chairman Allan Ritchie and newly appointed Managing Director David Ward have structured the company to maximize shareholder alignment. All four directors collectively own over 5% of Adavale and take their remuneration exclusively in shares rather than cash, ensuring minimal corporate overhead. This approach is backed by cornerstone investor Gleneden, who holds 20% of the company and brings decades of resources sector expertise.The technical progress at London-Victoria has been impressive. Phase 1 drilling delivered standout results including 48 meters at 0.82 grams per ton gold, with high-grade zones of 25 meters at 1.2 g/t located 100 meters below the existing pit. Significantly, this intercept occurred outside the current resource envelope, indicating substantial expansion potential. Ward's historical knowledge of the site—having worked for the previous operator—combined with the recent discovery of hundreds of historic BHP grade control maps, is accelerating targeting accuracy.The company employs a dual-strategy approach: advancing London-Victoria toward near-term production through tolling agreements with nearby Alkane Resources' Tomingley facility (50km away), while systematically exploring five greenfields licenses for epithermal and porphyry discoveries. Surface samples at the Ashes prospect have returned up to 10 grams per ton gold, demonstrating early-stage promise.With Phase 2 drilling currently underway at a cost-effective A$350,000 for 13-14 holes, Adavale is executing a capital-efficient program that maintains multiple pathways to value creation in a favorable gold price environment exceeding A$4,000 per ounce.Learn more: https://www.cruxinvestor.com/companies/adavale-resourcesSign up for Crux Investor: https://cruxinvestor.com

On episode #95 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 11/20/25 – 12/3/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Early low-dose dexamethasone is associated with shorter acute symptom duration in Chikungunya virus infection: a retrospective cohort study (BMC Infectious Diseases) Noninferiority of One HPV Vaccine Dose to Two Doses (NEJM) Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection (NEJM) Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human InfectionModel (NEJM) Universal Hepatitis B Vaccination at Birth—Risks of Revising the recommendation (JAMA) Correlates of HIV-1 control after combination immunotherapy (Nature) Human-to-Human Rabies Transmission via Solid Organ Transplantation from a Donor with Undiagnosed Rabies — United States, October 2024–February 2025 (CDC: MMWR) Cytomegalovirus-specific cell-mediated immunity for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir prophylaxis in donor CMV-seropositive recipient CMV-seronegative kidney transplant recipients (CID) An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant (CID) Bacterial Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update (CID) Lyme DiseaseIncidence in Massachusetts, 2012-2024 (JAMA: Open Network) Fungal The Last of US Season 2 (YouTube) Aspergillosis-Attributable Mortality in the United States: Analysis of Death CertificateData (CID) Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial (LANCET: Infectious Diseases) Parasitic Loa loa encephalopathy following treatment with benzimidazole derivatives: A systematic review (OFID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

How SaaS GTM Will Change in 2026? In this episode of the Grow Your B2B SaaS podcast, host Joran welcomes Glenn Miseroy, co-founder and CEO of Expandii, a cloud-based LinkedIn automation solution. Over the past six years, Expandii has grown to a team of 45 and scaled to 10 million ARR. The conversation digs into how go-to-market motions will evolve by 2026, why employee-led thought leadership will become central to growth, how AI will reshape ideation and timing, and why signal-based, intent-driven approaches must replace traditional lead lists. Glenn also shares how he would rebuild a go-to-market motion from scratch, how to operationalize signals across channels, and what founders should prioritize at different revenue stages—from zero to 10K MRR with founder-led growth to scaling toward 10 million ARR with clear ICP and aligned storytelling.Key Timecodes(0:00) - B2B SaaS Podcast Intro: GTM 2026, intent signals, LinkedIn thought leadership, AI(1:14) - Guest Intro: Glenn Miseroy, Expandi CEO, LinkedIn automation, 10M ARR(1:49) - 2026 GTM Vision: employee-led thought leadership, hybrid PLG + SLG(2:57) - AI for Thought Leadership: ideation, personalization, timing(3:34) - Defining Intent Signals: website visitors, LinkedIn profile views, post engagement, followers(4:13) - Signal-to-Intent: timing outreach with high-intent signals(5:10) - Full-Funnel GTM: thought leadership reach to multichannel outreach(5:42) - Rebuilding GTM 2026: team-led LinkedIn thought leadership strategy(6:49) - Phase 2: capture engagement signals, route to sales, no more lead lists(7:58) - Company-Level Intent + ABM: multi-contact warming, signal-based outreach(9:15) - Enabling Employee Advocacy: content ops, Scripe, AI content calendar(10:35) - Overcoming Posting Fear: ICP-first mindset on LinkedIn(12:00) - Sponsor: Reditus affiliate referral platform for B2B SaaS(12:57) - AI and Headcount: efficiency, enablement, process optimization(13:44) - 2026 Growth Loop: thought leadership pipeline, AI personalization, timing triggers(14:50) - Trigger-Based Outreach: new Head of Sales timing on LinkedIn(15:14) - 0–10K MRR: founder-led growth on LinkedIn, capture intent signals(16:39) - Scaling to 10M ARR: clear ICP, aligned messaging, storytelling(17:58) - Messaging Framework: problem-led narrative vs “10X meetings”(18:59) - Connect with Glenn: LinkedIn, Expandi website(19:11) - Outro CTA: subscribe, sponsor, Reditus info

Day 1,383.Today, after a weekend marked by continued talks in Florida between the Ukrainian and American delegations and President Donald Trump's comments blaming Zelensky for stalling negotiations, the Ukrainian president meets British PM Keir Starmer, French President Macron and German Chancellor Merz in London today. The talks, which finished as we were recording this episode, opened with Germany's ‘scepticism' of US peace proposals and France's assurance that ‘Europe had a lot of cards in its hands.' Meanwhile, Russia targets a dam near Kharkiv which supplies water to Ukraine's second biggest city. Finally, we discuss the US's National Security Strategy and the current state of Ukraine's air defence. ContributorsAdélie Pojzman-Pontay (Journalist and Producer). @adeliepjz on X.Dominic Nicholls (Associate Editor of Defence). @DomNicholls on X.With thanks to Michael Bohnert (RAND). @mbohnert on X.SIGN UP TO THE ‘UKRAINE: THE LATEST' WEEKLY NEWSLETTER:http://telegraph.co.uk/ukrainenewsletter Each week, Dom Nicholls and Francis Dearnley answer your questions, provide recommended reading, and give exclusive analysis and behind-the-scenes insights – plus maps of the frontlines and diagrams of weapons to complement our daily reporting. It's free for everyone, including non-subscribers.CONTENT REFERENCED:Zelenskiy Says No Accord Yet on Ukraine's East in US Talks, Bloomberg Newshttps://www.bloomberg.com/news/articles/2025-12-08/zelenskiy-says-no-accord-so-far-on-eastern-ukraine-in-us-talksTrump: Zelensky hasn't even read my peace plan, The Telegraphhttps://www.telegraph.co.uk/world-news/2025/12/08/ukraine-russia-war-latest-starmer-zelensky-trump-putin/Kremlin: Trump's new defence strategy ‘consistent' with Russian vision, The Telegraphhttps://www.telegraph.co.uk/world-news/2025/12/07/donald-trump-defence-strategy-russia-dmitry-peskov-kremlin/France shielding €18bn Russian asset pot from EU ‘reparations loan' push, Financial timeshttps://www.ft.com/content/fe304bb8-d928-4b9b-8162-2000301be937LISTEN TO THIS PODCAST IN NEW LANGUAGES:The Telegraph has launched translated versions of Ukraine: The Latest in Ukrainian and Russian, making its reporting accessible to audiences on both sides of the battle lines and across the wider region, including Central Asia and the Caucasus. Just search Україна: Останні Новини (Ukr) and Украина: Последние Новости (Ru) on your on your preferred podcast app to find them. Listen here: https://linktr.ee/ukrainethelatestSubscribe: telegraph.co.uk/ukrainethelatestEmail: ukrainepod@telegraph.co.uk Hosted on Acast. See acast.com/privacy for more information.

Order my new book: https://geni.us/AtlasOfUFOs The Tedesco brothers return with their most revealing Nightcrawler data yet. From advanced drone-like objects appearing across the East Coast to large luminous orbs shifting between visible, infrared and ultraviolet spectra, John and Gerald break down what their multi-sensor systems actually captured and why some of it defies prosaic explanation. They discuss why their research focus is shifting from UAPs to USOs, the recurring water connection, and several cases where objects appeared to respond to being observed. The brothers also detail a black triangle emerging from a cloud system, complete with radar tracks, RF disturbances and electromagnetic anomalies. With newly secured multi-year funding, Nightcrawler is expanding into deep-water surveys, hyperspectral detection and a full Phase 3 investigative programme. Plus, updates on their upcoming documentaries and what they expect to uncover next. A rare, data-driven look at phenomena unfolding both above and now beneath the surface.

Nicole and Diana give an overview of Diana's multi-phase research to discover the father of Cynthia (Dillard) Royston. Diana first reviews four past phases of her research. She discusses Phase 1, which initially focused on George W. Dillard as a strong candidate, and Phase 2, which identified and eliminated ten other Dillard candidates in the area. Both of these documentary-based hypotheses are eventually disproven. She then outlines Phase 3, where she successfully tests and disproves a false ThruLine DNA hypothesis that suggested Hopson Milner was the father. Next, Phase 4 adds DNA analysis to the quest, leading to a cluster of matches with a most recent common ancestor of Elijah Dillard, who is a possible brother or cousin to Cynthia. The project then pivots to Phase 5, based on a new record that places Cynthia's husband, Thomas B. Royston, in Cass County, Georgia, around the likely time of their marriage. This new location in Cass County, where early records were destroyed by fire, provides a new research objective: to discover a Dillard candidate residing there in the 1830s. Listeners learn how to methodically work through a complex brick wall by testing and eliminating both documentary and DNA hypotheses in a focused, systematic process. This summary was generated by Google Gemini. Links Revisiting the Father of Cynthia (Dillard) Royston: Part 1 Objective - https://familylocket.com/revisiting-the-father-of-cynthia-dillard-royston-part-1-objective/ Sponsor – Newspapers.com For listeners of this podcast, Newspapers.com is offering new subscribers 20% off a Publisher Extra subscription so you can start exploring today. Just use the code "FamilyLocket" at checkout.  Research Like a Pro Resources Airtable Universe - Nicole's Airtable Templates - https://www.airtable.com/universe/creator/usrsBSDhwHyLNnP4O/nicole-dyer Airtable Research Logs Quick Reference - by Nicole Dyer - https://familylocket.com/product-tag/airtable/ Research Like a Pro: A Genealogist's Guide book by Diana Elder with Nicole Dyer on Amazon.com - https://amzn.to/2x0ku3d 14-Day Research Like a Pro Challenge Workbook - digital - https://familylocket.com/product/14-day-research-like-a-pro-challenge-workbook-digital-only/ and spiral bound - https://familylocket.com/product/14-day-research-like-a-pro-challenge-workbook-spiral-bound/ Research Like a Pro Webinar Series - monthly case study webinars including documentary evidence and many with DNA evidence - https://familylocket.com/product-category/webinars/ Research Like a Pro eCourse - independent study course -  https://familylocket.com/product/research-like-a-pro-e-course/ RLP Study Group - upcoming group and email notification list - https://familylocket.com/services/research-like-a-pro-study-group/ Research Like a Pro Institute Courses - https://familylocket.com/product-category/institute-course/ Research Like a Pro with DNA Resources Research Like a Pro with DNA: A Genealogist's Guide to Finding and Confirming Ancestors with DNA Evidence book by Diana Elder, Nicole Dyer, and Robin Wirthlin - https://amzn.to/3gn0hKx Research Like a Pro with DNA eCourse - independent study course -  https://familylocket.com/product/research-like-a-pro-with-dna-ecourse/ RLP with DNA Study Group - upcoming group and email notification list - https://familylocket.com/services/research-like-a-pro-with-dna-study-group/ Thank you Thanks for listening! We hope that you will share your thoughts about our podcast and help us out by doing the following: Write a review on iTunes or Apple Podcasts. If you leave a review, we will read it on the podcast and answer any questions that you bring up in your review. Thank you! Leave a comment in the comment or question in the comment section below. Share the episode on Twitter, Facebook, or Pinterest. Subscribe on iTunes or your favorite podcast app. Sign up for our newsletter to receive notifications of new episodes - https://familylocket.com/sign-up/ Check out this list of genealogy podcasts from Feedspot: Best Genealogy Podcasts - https://blog.feedspot.com/genealogy_podcasts/

Welcome to The Times of Israel's Daily Briefing, your 20-minute audio update on what's happening in Israel, the Middle East and the Jewish world. US bureau chief Jacob Magid joins host Amanda Borschel-Dan for today's episode. Magid joins us from the Doha Forum, an annual gathering bringing together government officials, policymakers, civil society representatives and business leaders from around the world to discuss major global challenges. Qatar’s Prime Minister said yesterday that Doha does not consider the current situation in Gaza to be a ceasefire, arguing that this would require an Israeli withdrawal from the entirety of the enclave. At the same time, Egyptian Foreign Minister Badr Abdelatty called for deploying the International Stabilization Force (ISF) in Gaza “as soon as possible,” claiming that Israel is using the absence of international monitors on the ground in Gaza to violate the ceasefire on a daily basis. We hear additional statements critical of Israel and discuss their significance, even as the Trump administration appears to announce that Phase 2 of the Gaza ceasefire will commence in the coming weeks. Also yesterday at the Doha Forum, Syrian President Ahmed al-Sharaa accused Israel of “exporting crises” to other countries around the region to distract from its “horrifying massacres” in Gaza. We learn how those at the forum consider that the Syrian president, once denounced as a terrorist, is a legitimate actor in the region, whereas Israel is not. Piling on to the criticism against Israel at the forum, also yesterday, a senior Saudi diplomat said that while there is much focus in the international community on the need for the Palestinian Authority to engage in a comprehensive reform process, a reform of the Israeli government is what is most needed for peace in the region. Magid puts this new Saudi statement in the context of what we also learned yesterday: that the US and Saudi Arabia had reached understandings on the eve of Hamas’s October 7 attack regarding the concessions Israel would have to make vis-à-vis the Palestinians for Riyadh to normalize relations with Jerusalem. Magid previews what he has uncovered, which will be discussed more in depth in Friday's Lazar Focus podcast. Check out The Times of Israel's ongoing liveblog for more updates. For further reading: Qatari PM: Gaza truce can’t be considered ceasefire until Israel leaves the Strip Trump says next phase of his Gaza plan will soon commence amid concern it’s stalling Syria’s Sharaa slams Israel for ‘exporting’ conflict to region to hide Gaza ‘massacres’ Senior Saudi diplomat: It’s Israel, not PA , that most needs reform to secure peace ToI reveals: US and Saudis reached understandings on Palestinian component of normalization before Oct. 7 The day after that never came: How time ran out on Blinken’s plan for postwar Gaza Subscribe to The Times of Israel Daily Briefing on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. This episode was produced by Pod-Waves. IMAGE: (From L) CEO and President of the International Crisis Group Comfort Ero, Spain's Foreign Minister Jose Manuel Albares, Egypt's Foreign Minister Badr Abdelatty, Norway's Foreign Minister Espen Barth Eide and Saudi Cabinet of the Minister of Foreign Affairs's minister plenipotentiary Manal Radwan attend the opening day of the Doha Forum, an annual diplomatic conference, in Doha on December 6, 2025. (Mahmud HAMS / AFP)See omnystudio.com/listener for privacy information.

In this Huberman Lab Essentials episode, I explain how to create lasting habits and break unwanted ones. I explain two habit-building systems: one aligned with daily rhythms and another based on a 21-day cycle of forming and reinforcing habits. I also discuss why habit formation differs between individuals and how certain "linchpin" habits can make other behaviors easier to adopt. Finally, I share practical tools—including visualization, task bracketing, and methods for rewiring bad habits—to support lasting behavioral change. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman Eight Sleep: https://eightsleep.com/huberman LMNT: https://drinklmnt.com/huberman Timestamps (00:00) Habits (00:43) What are Habits?, Neuroplasticity (01:15) Goal-Based vs Identity-Based Habits (02:33) How Long Does It Take to Form a Habit?; Limbic Friction (05:31) Sponsor: Eight Sleep (06:59) Tool: Linchpin Habits (08:51) Habit Strength, Context Dependence & Limbic Friction (10:41) How We Form Habits, Tool: Review Procedural Steps (12:49) Tool: Task Bracketing (16:30) Sponsor: LMNT (18:02) Should You Schedule Habits?; Phase-Based Habit Plan (20:00) Phase 1 (Morning) & Challenging Habits (21:23) Phase 2 (Afternoon), Relaxation; Mellow Habits (24:46) Phase 3 (Evening), Enhancing Sleep & Habit Consolidation (28:00) Habit Flexibility & Daily Timing (30:33) Sponsor: AGZ by AG1 (32:02) Tool: 21-Day Habit Program; Habit Missteps (37:16) Tool: How to Break Habits & Replacement Behaviors (39:59) Recap Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Despite their support for Ukraine, European countries have been a significant market for Russian energy. But an agreement has now been reached between the European Council and the European Parliament to phase out imports of Russian gas. The announcement came as it emerged peace talks between the US and Russia had failed, once again, to produce a breakthrough. Also in this episode - France's President, Emmanuel Macron, has arrived in Beijing for an official visit that will also take him to the city of Chengdu. The search for missing Malaysia Airlines flight MH-370 will resume this month. A new draft law on conscripting ultra-Orthodox Jews has sparked uproar in Israel. The American city of San Francisco is to file the nation's first government lawsuit against manufacturers of ultra-processed food. The BBC investigates the dramatic rise in online abuse towards football players and managers in the Premier League and Women's Super League. And a man in New Zealand is being questioned after allegedly swallowing a Faberge diamond pendant, in an attempt to smuggle it out of a jewellery store.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.uk